4.7 Review

Clinical Tracking of Cell Transfer and Cell Transplantation: Trials and Tribulations

Journal

RADIOLOGY
Volume 289, Issue 3, Pages 604-615

Publisher

RADIOLOGICAL SOC NORTH AMERICA
DOI: 10.1148/radiol.2018180449

Keywords

-

Funding

  1. EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD081123] Funding Source: NIH RePORTER
  2. NATIONAL CANCER INSTITUTE [U54CA199075, R21CA190196] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054458] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB024495, R01EB023647] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK106972] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS098520] Funding Source: NIH RePORTER
  7. NIBIB NIH HHS [R01 EB023647, P41 EB024495] Funding Source: Medline
  8. NIDDK NIH HHS [R01 DK106972] Funding Source: Medline
  9. NINDS NIH HHS [R56 NS098520] Funding Source: Medline

Ask authors/readers for more resources

Cell therapy has provided unprecedented opportunities for tissue repair and cancer therapy. Imaging tools for in vivo tracking of therapeutic cells have entered the clinic to evaluate therapeutic cell delivery and retention in patients. Thus far, clinical cell tracking studies have been a mere proof of principle of the feasibility of cell detection. This review centers around the main clinical queries associated with cell therapy: Have cells been delivered correctly at the targeted site of injection? Are cells still alive, and, if so, how many? Are cells being rejected by the host, and, if so, how severe is the immune response? For stem cell therapeutics, have cells differentiated into downstream cell lineages? Is there cell proliferation including tumor formation? At present, clinical cell tracking trials have only provided information on immediate cell delivery and short-term cell retention. The next big question is if these cell tracking tools can improve the clinical management of the patients and, if so, by how much, for how many, and for whom; in addition, it must be determined whether tracking therapeutic cells in every patient is needed. To become clinically relevant, it must now be demonstrated how cell tracking techniques can inform patient treatment and affect clinical outcomes. (C) RSNA, 2018

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available